Therapeutics

Mayo Clinic’s 11th Annual Forensic Science Symposium is your opportunity to engage with leading experts and gain hands-on experience in critical areas of forensic investigation.[...]

We’ve created two new oral fluid specimen collection videos for controlled substance monitoring. The first video is designed to support healthcare professionals by outlining how to safely and effectively oversee a patient’s specimen collection. The second is from the patient’s perspective, giving them a step-by-step guide for what to expect during the collection process.

Viral and pharmacogenomic testing help clinicians detect infection early, tailor immunosuppression, and improve long-term outcomes for organ transplant recipients.

Presentation Recording Coming Soon - PACE/FL - Review the latest evidence, guidelines, strategies, and testing solutions for differentiating metabolic from alcohol-related liver injury.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.

The rapidly evolving field of pharmacogenomics, the DPYD gene and its significance in oncology.

As drug trends and diagnostic technologies evolve, toxicology must adapt to meet the demands of healthcare, workplace safety, and public health—focusing on opioid detection, CBD use, patient-centered testing, and new methods like saliva analysis, each bringing distinct challenges and opportunities. The following podcast episodes feature chemistry-related interviews that discuss these topics.

Reviewing the challenges healthcare providers face in distinguishing between new and residual marijuana use in patients.

PACE/State of FL - The critical role of pharmacogenomics and therapeutic drug monitoring (TDM) in managing immunosuppressive therapy for solid organ transplant recipients.

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

Kelly DuBois recently joined “Symptomatic: A Medical Mystery Podcast” to explain her health journey with Mayo Clinic. In the episode, Kelly, who faced a series of unexplained health issues over two decades, highlighted the help that Mayo Clinic was able to offer her after being misdiagnosed with acromegaly.

John Logan Black, M.D., explains how Mayo Clinic Laboratories' UGT1A1 tests (Mayo IDs: U1A1Q and UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.

PACE/State of FL - Substance use disorders and the common laboratory tests and matrices used for controlled substance monitoring.